精神分裂症的早期检测与预防性干预:从幻想到现实
该文综述了精神分裂症早期检测与干预的研究进展:首发精神病研究支持团队协作的专科照护作为早期精神病标准治疗,但临床高风险诊断标准特异性不足,尚无治疗被证明能降低或预防向综合征性精神病转化;未来需多中心大样本、方法学严谨且由可信病理生理理论指导的研究。
要点
- 首发精神病研究支持团队协作的专科照护作为早期精神病标准治疗。
- 临床高风险已有循证照护模型减轻 attenuated 症状负担,但无治疗被证明能降低向综合征性精神病转化的风险。
- 当前临床高风险诊断标准缺乏足够特异性,限制其临床应用。
核心结论
- 首发精神病研究为团队协作的专科照护作为早期精神病标准治疗提供了证据基础,并促使其全球推广。
- 临床高风险研究已开发循证照护模型以减轻 attenuated 症状负担,但尚无治疗被证明能降低风险或预防向综合征性精神病转化。
- 缺乏敏感且特异的症状前精神分裂症诊断标准、经验证生物标志物和被证明的治疗策略,限制了早期检测与干预模型潜力的实现。
研究设计与样本
- 本文为综述,汇总首发精神分裂症与临床高风险研究的相关发现。
主要发现
- 未治疗精神病症状持续时间与结局相关。
- 首发患者对 antipsychotics 的反应优于慢性病患者。
- 疾病过程中脑灰质体积减少。
- 早期检测与干预照护模型在限制患病率和改变疾病病程方面结果令人鼓舞但不 conclusive。
- 临床高风险已有循证照护模型减轻 attenuated 症状负担,但无治疗被证明能降低风险或预防向综合征性精神病转化。
关键数值与推荐
- 当前临床高风险诊断标准缺乏足够特异性用于临床应用。
- 尚无治疗被证明能降低或预防临床高风险向综合征性精神病转化。
临床怎么用
- 可考虑以团队协作的专科照护作为早期精神病标准治疗。
- 临床高风险可应用循证照护模型减轻 attenuated 症状负担。
- 临床高风险诊断标准特异性不足,临床应用需谨慎。
局限性
- 缺乏敏感且特异的症状前精神分裂症诊断标准。
- 缺乏经验证生物标志物。
- 缺乏被证明的治疗策略。
- 早期检测与干预照护模型的有效性结果不 conclusive。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Scientific progress in understanding human disease can be measured by the effectiveness of its treatment. Antipsychotic drugs have been proven to alleviate acute psychotic symptoms and prevent their recurrence in schizophrenia, but the outcomes of most patients historically have been suboptimal. However, a series of findings in studies of first-episode schizophrenia patients transformed the psychiatric field's thinking about the pathophysiology, course, and potential for disease-modifying effects of treatment. These include the relationship between the duration of untreated psychotic symptoms and outcome; the superior responses of first-episode patients to antipsychotics compared with patients with chronic illness, and the reduction in brain gray matter volume over the course of the illness. Studies of the effectiveness of early detection and intervention models of care have provided encouraging but inconclusive results in limiting the morbidity and modifying the course of illness. Nevertheless, first-episode psychosis studies have established an evidentiary basis for considering a team-based, coordinated specialty approach as the standard of care for treating early psychosis, which has led to their global proliferation. In contrast, while clinical high-risk research has developed an evidence-based care model for decreasing the burden of attenuated symptoms, no treatment has been shown to reduce risk or prevent the transition to syndromal psychosis. Moreover, the current diagnostic criteria for clinical high risk lack adequate specificity for clinical application. What limits our ability to realize the potential of early detection and intervention models of care are the lack of sensitive and specific diagnostic criteria for pre-syndromal schizophrenia, validated biomarkers, and proven therapeutic strategies. Future research requires methodologically rigorous studies in large patient samples, across multiple sites, that ideally are guided by scientifically credible pathophysiological theories for which there is compelling evidence. These caveats notwithstanding, we can reasonably expect future studies to build on the research of the past four decades to advance our knowledge and enable this game-changing model of care to become a reality.
引用
- Lieberman JA, Small SA, Girgis RR, et al. Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality. Am J Psychiatry. 2019. PMID: 31569988. doi:10.1176/appi.ajp.2019.19080865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。